2022年前列腺癌流行病学与危险因素更新——一项系统综述
该研究基于GLOBOCAN 2020数据及2022年7月对PubMed/MEDLINE和EMBASE的系统检索,综述前列腺癌描述性流行病学、大型筛查研究、诊断技术与危险因素;前列腺癌仍是全球男性第二常见癌症,筛查接受度上升可能降低死亡率但伴随过度诊断与过度治疗,MRI与生物标志物应用或可减轻筛查负面影响。
要点
- 前列腺癌是全球男性第二常见癌症,北美、南美、欧洲、澳大利亚和加勒比地区发病率最高。
- 危险因素包括年龄、家族史和遗传易感性,其他可能因素包括吸烟、饮食、体力活动、特定药物和职业因素。
- 筛查接受度上升可能降低前列腺癌死亡率,但代价是过度诊断和过度治疗。
核心结论
- 前列腺癌仍是全球男性第二常见癌症。
- 前列腺癌筛查接受度正在上升,可能以过度诊断和过度治疗为代价降低前列腺癌死亡率。
- 日益使用MRI和生物标志物检测前列腺癌可能减轻筛查的部分负面后果。
- 前列腺癌可避免的危险因素可能包括吸烟、饮食、体力活动、特定药物和某些职业等因素。
研究设计与样本
- 系统综述,2020年前列腺癌发病率和死亡率数据来自国际癌症研究机构GLOBOCAN数据库。
- 2022年7月使用PubMed/MEDLINE和EMBASE生物医学数据库进行系统检索。
- 综述按照系统综述和Meta分析优先报告条目(PRISMA)指南进行,并在PROSPERO注册(CRD42022359728)。
主要发现
- 全球范围内,前列腺癌是第二常见癌症,北美、南美、欧洲、澳大利亚和加勒比地区发病率最高。
- 危险因素包括年龄、家族史和遗传易感性;其他因素可能包括吸烟、饮食、体力活动、特定药物和职业因素。
- 随着前列腺癌筛查变得更被接受,MRI和生物标志物等较新方法已被用于识别可能携带显著肿瘤的患者。
局限性
- 本综述的局限性包括证据来源于多为回顾性研究的Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prostate cancer (PCa) is one of the most common cancers worldwide. Understanding the epidemiology and risk factors of the disease is paramount to improve primary and secondary prevention strategies. OBJECTIVE: To systematically review and summarize the current evidence on the descriptive epidemiology, large screening studies, diagnostic techniques, and risk factors of PCa. EVIDENCE ACQUISITION: PCa incidence and mortality rates for 2020 were obtained from the GLOBOCAN database of the International Agency for Research on Cancer. A systematic search was performed in July 2022 using PubMed/MEDLINE and EMBASE biomedical databases. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and was registered in PROSPERO (CRD42022359728). EVIDENCE SYNTHESIS: Globally, PCa is the second most common cancer, with the highest incidence in North and South America, Europe, Australia, and the Caribbean. Risk factors include age, family history, and genetic predisposition. Additional factors may include smoking, diet, physical activity, specific medications, and occupational factors. As PCa screening has become more accepted, newer approaches such as magnetic resonance imaging (MRI) and biomarkers have been implemented to identify patients who are likely to harbor significant tumors. Limitations of this review include the evidence being derived from meta-analyses of mostly retrospective studies. CONCLUSIONS: PCa remains the second most common cancer among men worldwide. PCa screening is gaining acceptance and will likely reduce PCa mortality at the cost of overdiagnosis and overtreatment. Increasing use of MRI and biomarkers for the detection of PCa may mitigate some of the negative consequences of screening. PATIENT SUMMARY: Prostate cancer (PCa) remains the second most common cancer among men, and screening for PCa is likely to increase in the future. Improved diagnostic techniques can help reduce the number of men who need to be diagnosed and treated to save one life. Avoidable risk factors for PCa may include factors such as smoking, diet, physical activity, specific medications, and certain occupations.
引用
- Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 2023. PMID: 37202314. doi:10.1016/j.eururo.2023.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。